Skip to main content
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. — Investor Relations & Filings

Ticker · NAGE ISIN · US1710774076 LEI · 529900OPI7B8JPXCVS70 US Manufacturing
Open in API
Filings indexed 954 across all filing types
Latest filing 2010-05-26 Director's Dealing
Country US United States of America
Listing US NAGE

About Niagen Bioscience, Inc.

https://www.niagenbioscience.com/

Niagen Bioscience, Inc. (formerly ChromaDex) is a bioscience company focused on the science of nicotinamide adenine dinucleotide (NAD+). The company aims to improve healthspan and support healthy aging by developing products that restore and optimize cellular NAD+ levels. Its core proprietary ingredient is Niagen®, a patented and clinically studied form of nicotinamide riboside (NR), a precursor to NAD+. Niagen® is the key component in the company's consumer dietary supplement brand, Tru Niagen®, and is also developed for the food, beverage, and pharmaceutical markets. The company's research is supported by numerous human clinical studies, a portfolio of over 50 owned and licensed patents, and collaborations with global research institutions.

Recent filings

Filing Released Lang Actions
Director's Dealing 2010
Director's Dealing
2010-05-26 English
Director's Dealing 2010
Director's Dealing
2010-05-26 English
8K PIPE
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about a private placement of equity securities (unregistered sales of shares and warrants) and changes in the company's board of directors and management structure. There are no financial statements or detailed financial performance data presented, so it is not an Annual Report (10-K) or Interim Report (IR). The document primarily announces financing activity and management/board changes. Given the significant focus on the private placement transaction, it fits best under Capital/Financing Update (CAP). Additionally, the document includes management changes, but since the financing update is the primary event and the document is a current report, CAP is the most appropriate classification. Confidence is high because the document explicitly details a private placement and related capital raising terms.
2010-05-25 English
8K VOTE RESULTS
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filing with the SEC, dated May 20, 2010, reporting the final voting results from the company's annual meeting of stockholders. It details the outcomes of votes on director elections, amendments to the certificate of incorporation, equity incentive plan changes, and appointment of the independent auditor. The key phrase 'Submission of Matters to a Vote of Security Holders' and the detailed vote counts confirm this is an official announcement of voting results. The document length is 3317 characters, which is relatively short and focused solely on voting results, not the full meeting materials or reports. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2010-05-25 English
MARK G FORM 4 2010
Director's Dealing
2010-05-25 English
HUGH D FORM 4 2010
Director's Dealing
2010-05-25 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.